Effect of age and dementia on the prevalence of cardiovascular disease

Martins, Cícero S. S.; Gambert, Steven; Gupta, Krishan Lal; Schultz, Barry M.

doi:10.1007/bf02432502

Cited by 10 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microvascular damage is characteristic of AD, 33–36 appears to be one of the earliest abnormalities in AD, 35 and is associated not only with cerebrovascular amyloidosis 33 but also with free‐radical mediated mechanisms 34 and with reduction in the number of glucose transporter complexes in the microvasculature 36 . In addition, cardiac disease has been found to be an independent risk factor for AD in clinical, 37 , 38 electrocardiographic, 39 pathological, 40 and experimental 41 studies.…”

Section: Discussionmentioning

confidence: 99%

Absence of Vascular Dementia in an Autopsy Series from a Dementia Clinic

Nolan

Lino

Seligmann

et al. 1998

J American Geriatrics Society

126

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Absence of Vascular Dementia in an Autopsy Series from a Dementia Clinic

Nolan

Lino

Seligmann

et al. 1998

J American Geriatrics Society

126

View full text Add to dashboard Cite

show abstract

“…Epidemiologic surveys suggest an association between risk of AD and presence of atherosclerotic heart disease (15–20), as well as a link between high fat/cholesterol diet and increased risk of AD (21–24). Cholesterol levels are increased in the blood of AD patients (21, 25–28), and increased cholesterol has been observed in the AD brain as a function of ApoE allotype (22, 29).…”

Section: Cholesterol In Admentioning

confidence: 99%

Statin therapy in Alzheimer's disease

Sparks¹,

Sabbagh²,

Connor³

et al. 2006

Acta Neurol Scand

View full text Add to dashboard Cite

Previous studies have suggested that statin therapy may be of benefit in treating Alzheimer's disease (AD). We initiated a double-blind, placebo-controlled, randomized (1:1) trial with a 1-year exposure to once-daily atorvastatin calcium (80 mg; two 40 mg tablets) or placebo among individuals with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score of 12-28]. Stable dose use of cholinesterase inhibitors, estrogen and vitamin E was allowed, as was the use of most other medications in the treatment of co-morbidities. We demonstrated that atorvastatin treatment produced significantly (P = 0.003) improved performance on cognition and memory after 6 months of treatment (ADAS-cog) among patients with mild-to-moderate AD. This superior effect persisted at 1 year (P = 0.055). This positive effect on the ADAS-cog performance after 6 months of treatment was more prominent among individuals entering the trial with higher MMSE scores (P = 0.054). Benefit on other clinical measures was identified in the atorvastatin-treated population compared with placebo. Accordingly, atorvastatin therapy may be of benefit in the treatment of mild-to-moderately affected AD patients, but the level of benefit produced may be predicated on earlier treatment. Evidence also suggests that atorvastatin may slow the progression of mild-to-moderate AD, thereby prolonging the quality of an afflicted individual's life.

show abstract

“…Most recently, two studies indicate that lack of education markedly increases the prevalence of dementia of the Alzheimer type in older individuals 36 , 38 . There are now two studies in which myocardial infarct was found to be a significant risk factor for AD in elderly subjects 39 , 40 …”

Section: Risk Factorsmentioning

confidence: 99%